Investment firm KKR buys Capsugel from Pfizer for $2.4bn
Affiliates of publicly traded investment firm Kohlberg Kravis Roberts & Co. LP have acquired Pfizer Inc.’s drug formulation and delivery division Capsugel for $2.375bn in cash.
- Drug Delivery
- Synthesis Technologies, Production Processes
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com